68164-77-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Cyano-3,6-dimethylpyridine is used as a building block for the synthesis of various pharmaceuticals. Its ability to undergo multiple chemical reactions allows for the creation of a wide range of drug molecules, contributing to the development of new medications and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Cyano-3,6-dimethylpyridine is utilized as a precursor in the production of agrochemicals. Its reactivity and compatibility with other chemical groups make it suitable for the synthesis of compounds used in crop protection and pest control.
Used in Fine Chemicals Industry:
2-Cyano-3,6-dimethylpyridine is employed as an intermediate in the synthesis of fine chemicals, which are high-purity chemicals used in various applications, including fragrances, dyes, and specialty chemicals.
Used as a Ligand in Coordination Chemistry:
2-Cyano-3,6-dimethylpyridine serves as a ligand in coordination chemistry, where it forms complexes with metal ions. These complexes have potential applications in catalysis, materials science, and other areas of chemistry.
Used as a Catalyst in Chemical Reactions:
2-Cyano-3,6-dimethylpyridine is also used as a catalyst to facilitate various chemical reactions, enhancing the reaction rates and improving the overall efficiency of the processes. Its catalytic properties make it valuable in the synthesis of a range of chemical products.

Upstream product

• 4986-05-4 2,5-dimethylpyridine N-oxide 
• 7677-24-9 trimethylsilyl cyanide 
• 88-10-8 N,N-diethylcarbamyl chloride 
• 589-93-5 2,5-dimethylpyridine 
• 151-50-8 potassium cyanide 
• 892665-90-6 2-cyano-3,6-dimethylpyridine 1-oxide 
• 18368-76-8 2 chloro-3-methylpyridine 
• 557-21-1 zinc(II) cyanide 
• 72093-14-2 3-Methyl-2-chloro-6-methyl-pyridine 

Downstream Products

• 848774-90-3 (3,6-dimethylpyridin-2-yl)methanol 

Relevant academic research and scientific papers

EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

POTASSIUM CHANNEL MODULATORS

Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.

AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein "R1", "RA-1", "R2", "R3", and "Het" are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

Discovery of functionally selective 7,8,9,10-tetrahydro-7,10-ethano-1,2,4- triazolo[3,4-a]phthalazines as GABAA receptor agonists at the α3 subunit

We have previously identified the 7,8,9,10-tetrahydro-7,10-ethano-1,2,4- triazolo[3,4-a]phthalazine (1) as a potent partial agonist for the 0.3 receptor subtype with 5-fold selectivity in binding affinity over α1. This paper describes a detailed investigation of the substituents on this core structure at both the 3- and 6-positions. Despite evaluating a wide range of groups, the maximum selectivity that could be achieved in terms of affinity for the α3 subtype over the α1 subtype was 12-fold (for 57). Although most analogues showed no selectivity in terms of efficacy, some did show partial agonism at α1 and antagonism at α3 (e.g., 25 and 75). However, two analogues tested (93 and 96), both with triazole substituents in the 6-position, showed significantly higher efficacy for the α3 subtype over the α1 subtype. This was the first indication that selectivity in efficacy in the required direction could be achieved in this series.

Preparation of cyanopyridines by direct cyanation

After pretreatment with nitric acid and trifluoroacetic anhydride, aqueous potassium cyanide converted pyridines 1a-1 into their corresponding 2-cyano derivatives 4a-1 in an average yield of 52%. Georg Thieme Verlag Stuttgart.